Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | XDH | P47989 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.59 |
| ▸ | IPMK | Q8NFU5 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.57 |
| ▸ | TUBB | P07437 | 1/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986381 | 0.89 | MAPT (0.71) | MAPTXDHABCC1ALDH1A1HPGD | |
| SCHEMBL12986562 | 0.86 | MAPT (0.58) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12986941 | 0.84 | ALDH1A1 (0.76) | MAPTCYP1B1CYP1A1ALDH1A1HPGD | |
| SCHEMBL12986397 | 0.83 | ALDH1A1 (0.60) | MAPTCYP1B1CYP1A1TUBB4ATUBB | |
| SCHEMBL12986716 | 0.80 | EGFR (0.62) | MAPTCYP1B1CYP1A1CYP1A2XDH | |
| SCHEMBL12986680 | 0.79 | KDR (0.65) | MAPTCYP1B1CYP1A1CYP1A2TUBB4A | |
| SCHEMBL12986712 | 0.78 | EGFR (0.64) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30677926 | 0.76 | MAP1LC3B (0.68) | MAPTCYP1B1CYP1A1CYP1A2KDM1A | |
| SCHEMBL29115331 | 0.76 | MAP1LC3B (0.68) | MAPTCYP1B1CYP1A1CYP1A2KDM1A | |
| SCHEMBL12985974 | 0.76 | EGFR (0.61) | MAPTCYP1A2ALDH1A1HPGDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026098924-A1 | PROCESSING DEVICE INCLUDING A TRAM MEMORY | FOTONATION LIMITED (IE) | 2026-05-15 | — | — | WO | disclosed |
| US-12519564-B2 | Systems and methods for dual list decoding of convolutional codes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250336063-A1 | Multimodal Deep Learning to Differentiate Tumor Recurrence from Treatment Effect in Human Glioblastoma | UNIV VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250310030-A1 | Systems and Methods for Dual List Decoding of Convolutional Codes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4619373-A1 | METHOD FOR MANUFACTURING SYNTHETIC VANILLIN | Deasyl SA (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-12377103-B2 | Use of bromodomain-containing protein 9 inhibitors to treat and/or prevent uterine leiomyosarcoma | THE UNIVERSITY OF CHICAGO (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025057018-A1 | EXPRESSION VECTOR FOR RECOMBINANT U-CONOTOXIN THIA OR TIIIALAMUT EXPRESSION IN E.COLI | Science4Beauty Sp. z o.o. (PL) | 2025-03-20 | — | — | WO | disclosed |
| US-20250082823-A1 | IMPLANT AND COATING TO REDUCE OSTEOLYSIS | Sanford Burnham Prebys Medical Discovery Institute | 2025-03-13 | — | — | US | disclosed |
| CN-111684343-B | Optical method and apparatus | 牛津大学科技创新有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2022234128-A1 | APPARATUS AND METHOD BASED ON MEMRISTIVE COMPUTING PARADIGMS THAT ARE BASED ON A DOMINO PROCESSING UNIT | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-11-10 | — | — | WO | disclosed |
| US-11495326-B2 | Metagenomic library and natural product discovery platform | ZYMERGEN INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-105283547-B | Recombinant host cells for biosynthetic production | 罗地亚经营管理公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-109414487-B | Compositions and methods utilizing STAT1/3 inhibitors with oncolytic herpes viruses | 复诺健生物科技加拿大有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220184197-A1 | MULTI-SUBUNIT VACCINES TO ELICIT BOTH MHC- AND CD1-RESTRICTED T CELL RESPONSES | NORTHWESTERN UNIVERSITY | 2022-06-16 | — | — | US | disclosed |
| CN-114432327-A | Application of flavonoid carbon glycoside compound in preparation of medicine for preventing or treating acute lung injury and/or acute respiratory distress syndrome | 苏州凯祥生物科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022081992-A1 | METHODS FOR SUPPORTING GRAIN INTENSIVE DIETS IN RUMINANTS WITH ADMINISTRATION OF CHORDICOCCUS SP. | NATIVE MICROBIALS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114365747-A | Antifungal methylobacterium compositions and methods of use | 新叶共生有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3545657-B1 | SYSTEMS AND METHODS FOR DECODING OF MODULATED SYMBOLS OR COMPENSATING CHANNEL FREQUENCY RESPONSE OF THE MODULATED SYMBOLS | HUAWEI TECH CO LTD (CN) | 2022-04-13 | — | — | EP | disclosed |
| CN-108037481-B | Robustness gradable sparse array frequency and DOA estimation method and device | 天津大学 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377103-B2 | Use of bromodomain-containing protein 9 inhibitors to treat and/or prevent uterine leiomyosarcoma | BRD9, BRDT, BRD2 | MAPT 4268/4885CYP1B1 4422/4885CYP1A1 4798/4885 |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | RB1, ERCC4, TP53 | MAPT 3076/4885CYP1B1 3125/4885CYP1A1 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.